The Aseptic Fill Finish Market Size is predicted to record at a 10.67% CAGR during the forecast period for 2023-2031.
Aseptic processing is an important step in drug manufacturing as it involves aseptically filling and packaging medicinal products into containers. The risk of microbial contamination is very high in aseptic filling. Therefore, the aseptic filling should be carried out in a controlled environment to minimize drug exposure to factors that may adversely affect its stability and performance. This helps to extend the shelf life of the drug.
Pharmaceutical manufacturers with limited funds and capacity may find it difficult to meet the needs of consumers due to the high cost of specialized equipment and qualified professionals for these jobs. Therefore, many players outsource their needs by contracting with service providers to enhance production efficiency, reduce downtime, minimize waste production, and increase overall productivity. This, in turn, results in driving demand for the aseptic fill finish market.
Advanced technologies, such as robotics and single-use systems, are being adopted to improve the accuracy, efficiency and safety of aseptic fill finish procedures. Further, automated aseptic filling systems reduce human interference and can meet various operational requirements, from raw material loading to equipment cleaning.
Competitive Landscape:
Some of the Key Players in the Aseptic Fill Finish Market:
- AbbVie Contract Manufacturing
- Asymchem
- Aenova
- APL
- BioPharma Solutions
- BioReliance
- Boehringer Ingelheim BioXcellence
- Catalent Biologics
- Charles River Laboratories
- CordenPharma
- Delpharm
- Fareva
- Fresenius Kabi
- Glaxo SmithKline
- Hetero Drugs
- Intas Pharmaceuticals
- Lonza
- Pierre Fabre
- Pfizer CentreOne
- Plastikon Healthcare
- Patheon
- PiSA Farmaceutica
- Recipharm
- Wacker Biotech
- Syngene
- Sharp Services
- Siegfried
- Takara Bio
- WuXi Biologics
- Wockhardt
- Other Prominent Players
Market Segmentation:
The aseptic fill finish market is segmented based on the type of molecules, type of packaging containers, type of drug products, target therapeutic area, scale of operation, and company size. By molecules, the market is bifurcated into small molecules and biologics. The type of packaging containers segment comprises ampoules, cartridges, syringes and vials. By drug product types, the market is categorized into antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines, and other products.
Based on the target therapeutic area, the market is divided into autoimmune disorders, cardiovascular disorders, infectious diseases, oncological disorders, and other disorders. By the scale of operation, the market is sub-segmented into preclinical/clinical and commercial. The company size segment is grouped into large, mid-sized and small companies.
The Biologics Segment Dominated The Aseptic Fill Finish Market In 2022
The Biologics segment dominated the aseptic fill finish market in 2022. The rising importance of biologics and the increasing number of approvals contribute to the market growth. The fill & finish services are mainly done for biologics or large molecules, which are mostly commercialized as injectables. Hence, the growing demand for such drug products simultaneously supports the need for its fill-finish services, thus propelling the overall market growth. In addition, increasing demand for small molecules is likely to support the growth of the small molecules-based fill-finish segment during the forecast period.
They have several benefits over other container types, such as reduced medication errors, fast and safe administration and preparation, longer storage, and a lower risk of overfill, all of which result in development costs and reduced batch volumes. Hence, due to the aforementioned factors, the segment is poised to witness considerable growth across the forecast period.
The Vials Segment Is Expected To Be The Fastest-Growing Segment During The Forecast Period
The vials and syringes segments are anticipated to hold the highest market share across the projected period. This growth is due to fast and safe administration and preparation, lower risk of overfill, and increasing technological advancements in vials and syringes filling equipment. Moreover, most biologics and vaccines are filled in vials for safety and to avoid leakage.
Additionally, many contract manufacturing services are focusing on the technological innovations of vial filling to make an efficient and safe fill-finish process. For instance, in February 2022, CDMO Recro Pharma, Inc. announced the addition of new lyophilization features to its contract manufacturing offerings. The company's fill& finish aseptic pack will feature a fully automated, sterile vial filling platform capable of filling 2,000 pre-sterilized vials per hour.
The Cell Therapies Segment Is Projected To Grow At The Highest Rate In The Aseptic Fill Finish Market During The Forecast Period
Cell therapy is expected to be the fastest-growing segment over the forecast period. Increasing business collaborations and product innovations can create more opportunities for players to achieve considerable business & product success.
Regionally, Asia Pacific Led The Aseptic Fill Finish Market In 2022
Asia Pacific dominated the aseptic fill finish market in 2022 and is expected to continue its trend over the forecast period 2023-2031, owing to the rising demand for drugs & vaccines, advancements in the biopharmaceutical industries, developments in R&D infrastructure, and increasing CMOs in this region.
In addition, North America accounted for the largest share of the aseptic fill finish market, followed by Europe. Factors responsible for growth in this region are the growing chronic diseases, extensive R&D activities, surging M&A activities, and the increasing innovations of biopharmaceutical and pharma products.
Aseptic Fill Finish Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 10.67 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Molecules, By Type of Packaging Containers, By Type of Drug Products, By Target Therapeutic Area, By Scale of Operation, By Company Size |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aenova, AbbVie Contract Manufacturing, APL, Asymchem, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories, CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Patheon, Pfizer CentreOne, Plastikon Healthcare, PiSA Farmaceutica, Recipharm, Sharp Services, Wacker Biotech, Syngene, Takara Bio, WuXi Biologics, Siegfried, Wockhardt, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
